Cramer said this stock may be his best pick in the entire history of the Mad Money TV show.
And that's a long time. Mad Money has been on the air for almost 9 years!
So what stock stands head and shoulders above the many, many others?
"I have to tell you, Regeneron may be the best stock pick in the history of this show," Cramer said in his conversation with CEO Dr. Len Schleifer on Tuesday's broadcast.
Cramer first recommended the biotech in the spring of 2005. "when Schleifer first came on and told us a very positive, albeit very speculative story," Cramer explained.
Adam Jeffery | CNBC
At the time, Regeneron was trading at less than $5 a share. Flash forward to Tuesday January 14th – Regeneron printed $300. That's a whopping gain in excess of 5000%
But despite those sharp gains, Cramer doesn't think the run is over. Not by a long shot. "Remember biotech is a bet on new drugs the company has in the pipeline," Cramer explained.
And Regeneron has some potential blockbusters.
"Today we got even more good news about Eylea, the company's macular degeneration drug at the JP Morgan conference, where Regeneron said that this drug did $400 million in sales last quarter, substantially better than expected. Also, they're working on new indications for Eylea, including an important phase 3 diabetic macular edema trial."
And that may only be the tip of the proverbial iceberg.
"Also Regeneron has a new anti-cholesterol drug that can be used for all who can't tolerate traditional statin treatment," Cramer added. "And they have an anti-arthritis drug in the works that could also be a blockbuster."
All told, Cramer believes the path of least resistance remains higher.
"As I often tell you, I count Regeneron among the four horsemen of the big pharma apocalypse," Cramer said. (The others are Celgene, Biogen and Gilead). It's the kind of fast-growing biotech company that's a hotbed of innovation."
Call Cramer: 1-800-743-CNBC
Questions for Cramer? email@example.com
Questions, comments, suggestions for the "Mad Money" website? firstname.lastname@example.org